InSilico Medicine Announces Major Milestone in CKD Anemia Drug Collaboration with TaiGen

Key Highlights of the Announcement

• First Human Enrollment & Dosing Completed: InSilico Medicine Cayman TopCo (“InSilico Medicine”) has announced that ISM4808, an AI-driven PHD inhibitor targeting chronic kidney disease (CKD)-related anemia, has achieved its first clinical milestone. The first subject has been enrolled and dosed in a Phase I clinical trial led by TaiGen Biotechnology.
• Trial Design: The Phase I study is a randomized, double-blind, placebo-controlled trial, featuring both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts. The trial aims to evaluate safety, tolerability, and the pharmacokinetic profile of ISM4808 in healthy adults.
• Collaboration Details: In December 2025, InSilico Medicine entered a licensing agreement with TaiGen Biotechnology, granting TaiGen exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China (including Chinese mainland, Hong Kong, Macau, and Taiwan).
• Financial Structure: The deal includes an upfront payment, development and sales-based milestone payments, and tiered royalties on net sales. The total potential deal value is in the double-digit million dollar range.
• Company Overview: InSilico Medicine, a pioneer in integrating artificial intelligence and automation into drug discovery, was listed on the Hong Kong Stock Exchange (Stock code: 03696.HK) on December 30, 2025.
• Target Therapeutic Areas: The company is committed to providing innovative solutions for unmet medical needs including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Its AI platform, Pharma.AI, extends into advanced materials, agriculture, nutritional products, and veterinary medicine.

Potentially Price Sensitive Information for Investors

• Clinical Progress: Successful enrollment and dosing of the first human subject in Phase I is a critical milestone, reflecting positive progress in the development of ISM4808. Clinical advancement often impacts investor sentiment, especially in biotech stocks.
• Financial Impact: The licensing agreement with TaiGen includes milestone payments and royalties, which could substantially enhance InSilico Medicine’s revenue once ISM4808 progresses through clinical phases and is commercialized in Greater China.
• Strategic Expansion: The exclusive development rights in Greater China strengthen InSilico Medicine’s market presence in one of the world’s largest pharmaceutical markets, potentially accelerating commercial success.
• AI-driven Drug Discovery: The use of AI and automation in drug development is a disruptive approach that could lead to faster, cost-effective innovation, which may attract further investor interest and partnerships.
• Risks and Uncertainties: The company cautions that there is no guarantee of successful outcomes for clinical trials or business developments. Financial data disclosed has not been audited, and investors should exercise caution.

Executive Leadership and Governance

The board of directors comprises a mix of executive, non-executive, and independent directors, led by Mr. Aleksandrs Zavoronkovs, Ph.D., who serves as Chairman, CEO, and CBO. This experienced leadership team is likely to drive future innovation and business growth.

Conclusion

The completion of first human enrollment and dosing in the Phase I clinical trial for ISM4808 represents a significant advancement in InSilico Medicine’s pipeline and validates its AI-powered approach to drug discovery. The exclusive collaboration with TaiGen and the potential for milestone payments and royalties are key value drivers. Investors should monitor subsequent clinical results and commercialization progress that may affect the company’s valuation.

Disclaimer

This article contains forward-looking statements regarding InSilico Medicine’s business development, clinical progress, and financial prospects, which are subject to risks, uncertainties, and may not occur as expected. The financial data mentioned is unaudited. Investors are advised to perform their own due diligence and consult professional advisers before making investment decisions. No part of this article should be construed as financial advice.

View INSILICO Historical chart here